相关实验视频
Updated: Jul 21, 2025

07:44
Localization of the Locus Coeruleus in the Mouse Brain
Published on: March 7, 2019
17.9K
在神经退行性疾病中,Locus Coeruleus和诺拉德仁基药理学
Rachel A Matt1, Renee S Martin2, Andrew K Evans3
1CuraSen Therapeutics Inc., San Carlos, CA, USA. matt@curasen.com.
Handbook of experimental pharmacology
|July 26, 2023
概括
准大脑上腺受体 (ARs) 可能治疗神经退行性疾病. 刺激这些受体可以改善认知功能和大脑健康,为阿尔茨海默氏症和帕金森症等疾病提供了有前途的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 神经退行性疾病 神经退行性疾病
背景情况:
- 在阿尔茨海默氏症和帕金森氏症的早期病理学中, Locus coeruleus 变性导致 noradrenergic 基调的降低.
- 上腺体受体 (ARs) 调解上腺素的作用,影响认知功能,神经代谢,脑血流和神经炎症.
研究的目的:
- 审查大脑上腺受体的表达和功能.
- 探索针对神经退行性疾病的上腺受体的治疗潜力.
主要方法:
- 对上腺激素刺激和认知功能的临床前研究的综述.
- 对人类药物流行病学数据和临床试验的分析.
主要成果:
- 上腺素刺激可以逆转认知缺陷,并在诺亚上腺素耗尽的模型中支持大脑健康.
- 人类数据表明,上腺受体是神经退行性疾病的可行的治疗点.
结论:
- 上腺受体代表治疗认知症状和修改神经退行性疾病疾病进展的有希望的目标.
- 目前正在研究药理策略,包括抑制再吸收和直接激活受体.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Alzheimer's Disease: Overview
524
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
524
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
155
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
155

